Abstract:Abstract Background Since 2015, China has been rolling out the pricing reform for drugs and medical services (PRDMS) in the urban public hospitals in order to reduce drug expenditures and to relieve financial burdens of patients. This study aims at evaluating the effectiveness of the reform and investigating its positive impacts and unintended consequences to provide evidence basis for further policy making. Methods The Difference-in-difference (DID) approach was employed to analyze the reform impacts on the 31 provincial administrative areas in China based on data abstracted from China Statistics Yearbooks and China Health Statistics Yearbooks from 2012 to 2018. Results The reform resulted in a decrease of 7.59% in drug cost per outpatient visit, a decrease of 5.73% in drug cost per inpatient admission, a decrease of 3.63% in total cost per outpatient visit and an increase of 9.10% in surgery cost per inpatient admission in the intervention group. However, no significant change in examination cost was found. The reduction in the medical cost per inpatient admission was not yet demonstrated, nor was that in the total outpatient/ inpatient expenses. The nationwide pricing reform for drugs and medical services in urban public hospitals (PRDMS-U) in China is demonstrated to be effective in cutting down the drug expenditures. However, the revealed unintended consequences indicate that there are still significant challenges for the reform to reach its ultimate goal of curbing the medical expenditures. Conclusion We conclude that the pricing reform alone may not be enough to change the profit-driven behavior of medical service providers as the root cause lies in the unchanged incentive scheme for providers in the service delivery. This holds lessons for policy making of other low- and middle-income countries (LMICs) with similar health systems set up in the achievement of Universal Health Coverage (UHC).

Analysis of the "regulation of Drug Price Difference (trial Implementation)" in China

Experience and Enlightenment of Drug Price Regulation in Germany,Japan and Taiwan Area of China

Comparison of the Retail Drug Prices between China and Other Developed Countries or Districts

Cause Analysis of High Price Differences Drugs Before and After the Deregulation of Drug Price Control: Empirical Study with big data on drug price data of 16 provinces in China

Comparative Study on the Policies of Drug Price and Expenditure Control in China and Other Countries

Impact on Hospital Medicine After Adjusting the Drug Pricing Method

International Comparison of Drug Price Level in China

The International Regulation Methods of Pharmaceutical Pricing and Their Impacts:A Systematic Review

The Impact of the Reference Pricing Policy in China on Drug Procurement and Cost

Comparative analysis on the price of essential medicines:Based on the sample survey of primary health care institutions and pharmacies in 18 provinces

The impacts and unintended consequences of the nationwide pricing reform for drugs and medical services in the urban public hospitals in China

Analysis of the Feasibility of Setting Differential Margin Mode for Drug Selling in Public Hospitals in China

Intended and Unintended Impacts of Price Changes for Drugs and Medical Services: Evidence from China.

Empirical Research of Price Difference and Market Share Between Brand-Name Drugs and Generics in One Province in China

Drug pricing reform in China: analysis of piloted approaches and potential impact of the reform.

Deregulation and Pricing of Medical Services A Policy Experiment Based in China

Design of differential margin mode of drug selling in public hospitals

Evaluating the Effects of China's Price Regulation on Pharmaceutical Market During 1997～2008

Policy options for pharmaceutical price regulation

Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts

A systematic review on the impact of the volume-based procurement policy on prices and dosages of drugs